You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR RIOMET ER

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Riomet Er

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00087516 ↗	Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-06-01	The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00443755 ↗	Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance	Completed	National Center for Research Resources (NCRR)	Phase 2	2005-08-01	The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗	Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2005-08-01	The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗	Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance	Completed	Takeda Pharmaceuticals North America, Inc.	Phase 2	2005-08-01	The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗	Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance	Completed	Mayo Clinic	Phase 2	2005-08-01	The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00682448 ↗	Metformin for the Prevention of the Metabolic Side-effects of Zyprexa	Completed	Eli Lilly and Company	Phase 4	2007-08-01	We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
NCT00682448 ↗	Metformin for the Prevention of the Metabolic Side-effects of Zyprexa	Completed	Rush University Medical Center	Phase 4	2007-08-01	We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Riomet Er

Condition Name

Chart
Table

Condition Name for Riomet Er
Intervention	Trials
Insulin Resistance	4
Type 2 Diabetes Mellitus	4
Type 2 Diabetes	3
Diabetes	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Riomet Er
Intervention	Trials
Diabetes Mellitus	11
Diabetes Mellitus, Type 2	7
Insulin Resistance	5
Metabolic Syndrome X	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Riomet Er

Trials by Country

Map
Table

Trials by Country for Riomet Er
Location	Trials
United States	146
Mexico	4
South Africa	4
Canada	4
Russian Federation	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Riomet Er
Location	Trials
California	7
Pennsylvania	7
Ohio	7
North Carolina	6
Colorado	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Riomet Er

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Riomet Er
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	7
Phase 2/Phase 3	2
[disabled in preview]	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Riomet Er
Clinical Trial Phase	Trials
Completed	18
Recruiting	7
Active, not recruiting	6
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Riomet Er

Sponsor Name

Chart
Table

Sponsor Name for Riomet Er
Sponsor	Trials
National Cancer Institute (NCI)	6
Merck Sharp & Dohme Corp.	4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	3
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Riomet Er
Sponsor	Trials
Other	44
Industry	19
NIH	19
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.